Head to Head Stocks: Uranium Energy Corp. (NYSE:UEC), Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)

u.s stocks update

Uranium Energy Corp. (NYSE:UEC)

Uranium Energy Corp. (NYSE:UEC) closed at $1.26 on the last trading session with an increase of 0%, whereas, it previously closed at $1.26. The company has a market capitalization of $218.58 Million. The company traded shares of 0 on the trading day while its three month average volume stands at 1.2 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Uranium Energy Corp. (NYSE:UEC) produced diluted EPS of -0.12. The EPS estimate for next year as estimated by analysts is at -0.05 while EPS for next quarter is estimated at 0. Earnings per Share growth for this year is reported at 18, while the analysts estimated the EPS growth for next year at -0.05% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 14.8%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Uranium Energy Corp. (NYSE:UEC) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Uranium Energy Corp. (NYSE:UEC) stands at 0 and Price to Book or P/B for the most recent quarter stands at 3.23. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Uranium Energy Corp. (NYSE:UEC) are reported at 0.7 and 0.7 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Uranium Energy Corp. (NYSE:UEC) stands at -19.5, -27.4 and 0 respectively

The trailing twelve month Revenue of Uranium Energy Corp. (NYSE:UEC) is reported at 0 with income of -18100000. The outstanding shares of Uranium Energy Corp. (NYSE:UEC) are 173.48 Million. The institutional Ownership of the shares of 34.7 stands at 0.80%, this figure is increased 8.79 in the last six months. The insider ownership for the shares of Uranium Energy Corp. (NYSE:UEC) is ticked at 2.1%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Uranium Energy Corp. (NYSE:UEC) is the Mean Target Price estimated by the analysts which stands at 3.27. The 52 week high of Uranium Energy Corp. (NYSE:UEC) is placed at 2.00 and 52 week low is standing at 1.20.

Performance wise the shares of Uranium Energy Corp. (NYSE:UEC) fell down -2.33% for the week, it also fell -5.26% for the monthly performance, while for the quarter it went up -23.17%. The shares decrease -27.17% for the half year and plummeted for the Year-To-Date performance. The shares of Uranium Energy Corp. (NYSE:UEC) shrinked -15.44% for the yearly performance.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) closed at $40.87 on the last trading session with an increase of 0%, whereas, it previously closed at $40.87. The company has a market capitalization of $1.91 Billion. The company traded shares of 0 on the trading day while its three month average volume stands at 546.86 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) produced diluted EPS of -6.02. The EPS estimate for next year as estimated by analysts is at -1.51 while EPS for next quarter is estimated at -0.85. Earnings per Share growth for this year is reported at -20.8, while the analysts estimated the EPS growth for next year at -1.51% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 24.2%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) stands at 197.19 and Price to Book or P/B for the most recent quarter stands at 6.65. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) are reported at 6.9 and 7 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) stands at -71.3, -114.7 and 0 respectively

The trailing twelve month Revenue of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) is reported at 9.7 Million with income of -239600000. The outstanding shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) are 46.8 Million. The institutional Ownership of the shares of 0 stands at 0.80%, this figure is increased 10.75 in the last six months. The insider ownership for the shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) is ticked at 1.5%, the figure is plummeted -44.64% in the last six months.

Some other important financial aspects to be discussed here for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) is the Mean Target Price estimated by the analysts which stands at 83.1. The 52 week high of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) is placed at 74.75 and 52 week low is standing at 38.50.

Performance wise the shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rose up 5.85% for the week, it also fell -24.09% for the monthly performance, while for the quarter it went up -30.67%. The shares decrease -35.18% for the half year and plummeted for the Year-To-Date performance. The shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) shrinked -33.44% for the yearly performance.